Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial

Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial

ObjectivesTo examine the long-term survival outcome of dabrafenib in combination with trametinib in Chinese patients with unresectable or metastatic acral/cutaneous melanoma with BRAF-V600 mutation and to explore potential predictors of effectiveness.MethodsThis was a long-term follow-up of Chinese...

Full description

Bibliographic Details
Main Authors: Lili Mao, Ya Ding, Xue Bai, Xinan Sheng, Jie Dai, Zhihong Chi, Chuanliang Cui, Yan Kong, Yun Fan, Yanjun Xu, Xuan Wang, Bixia Tang, Bin Lian, Xieqiao Yan, Siming Li, Li Zhou, Xiaoting Wei, Caili Li, Jun Guo, Xiaoshi Zhang, Lu Si
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Oncology
Subjects:
melanoma
dabrafenib
trametinib
BRAF
acral melanoma
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.720044/full

Similar Items

Similar Items